Related Experiment Videos
Therapy strategies for multiple myeloma: current status.
Heinz Gisslinger1, Mathias Kees
1Division of Haematology and Blood Coagulation, Department of Internal Medicine I, University of Vienna, Vienna, Austria. heinz.gisslinger@akh-wien.ac.at
Wiener Klinische Wochenschrift
|September 19, 2003
Summary
Multiple myeloma (MM) treatment involves chemotherapy and stem-cell rescue, with newer therapies like thalidomide and bisphosphonates showing promise. These advanced treatments target myeloma cells and their bone marrow environment for improved patient outcomes.
Area of Science:
- Hematology
- Oncology
- Immunology
Background:
- Multiple myeloma (MM) is a cancer of plasma cells in the bone marrow.
- MM causes impaired blood cell production, reduced antibody function, and bone lesions.
- Current treatments include chemotherapy, high-dose therapy with stem-cell rescue, and supportive care.
Purpose of the Study:
- To review current and emerging therapeutic strategies for multiple myeloma.
- To highlight the role of novel agents targeting the tumor microenvironment.
- To discuss the management of skeletal complications in MM.
Main Methods:
- Literature review of established and investigational MM therapies.
- Analysis of treatment outcomes for conventional and novel approaches.
- Evaluation of supportive care measures, including bisphosphonates.
Main Results:
- High-dose therapy with stem-cell rescue improves survival in younger patients.
- Thalidomide and its derivatives offer promising new treatment avenues.
- Bisphosphonates are crucial for managing skeletal complications and show antitumor effects.
Conclusions:
- MM treatment is evolving with targeted therapies and immunomodulatory drugs.
- Addressing the bone marrow microenvironment is key to improving MM therapy.
- Bisphosphonates play a dual role in supportive care and direct antitumor activity.